



Consultant in Palliative Medicine, Dove House Hospice, Hull, United Kingdom
Management of diabetes mellitus 
in terminally ill cancer patients
Abstract
Many patients not only with cancer cared for by palliative care services suffer of diabetes. Treatment of dia-
betes in palliative care differs markedly from general medicine. Patients in palliative care usually have short 
prognosis and treatment targets are related more to the possible symptoms of hyper- or hypo-glycaemia 
and less to prevention of long term complications. Therefore monitoring of plasma blood glucose can be 
done less often. In this article we discuss all aspects of plasma glucose control in terminally ill. We also 
discuss problem of hyperglycaemia induced by steroids. The use of oral hypoglycaemic agents and insulin, 
together or separately, is discussed in detail. For patients near the end of life and on insulin, we propose 
a scheme with once daily plasma glucose monitoring and once daily administration of long acting insulin.
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Introduction
Diabetes mellitus is a common disease among 
the elderly. Approximately 10% of older pa-
tients have abnormal levels of blood glucose 
and/or abnormal glucose tolerance tests (GTT). 
Most of these patients (90%) will have regulatory, 
type II diabetes mellitus; only one in ten of the 
patients will be insulin dependent (type I diabe-
tes mellitus). 
There are no reliable statistics about the preva-
lence of diabetes among terminally ill cancer pa-
tients, but it is probable that the prevalence of diabe-
tes is higher than in the elderly population. If tested 
using a GTT, approximately 37% of non-diabetic 
patients with advanced cancer would be classified 
as diabetics [1]. Important common features for both 
diabetes type II and cancer are: 
—  insulin resistance in the liver and increased he-
patic glucose production;
—  increased glucose recycling;
—  reduced glucose utilization by the skeletal mus-
cles;
—  reduced skeletal muscle glycogen synthesis. 
One important difference, however, is that in can-
cer there is a lack of hyperinsulinism [2]. The mecha-
nism of cancer-related glucose intolerance is poorly 
understood, although it may be related to the onset 
of cancer cachexia. There may be tumour-specific fac-
tors that induce glucose intolerance by influencing 
the insulin receptors.
Patients with diabetes are also more likely to suf-
fer from cancer [3, 4]. Insulin is a “growth factor” 
and may by itself stimulate the growth of diverse tu-
mours. All of this results in a high frequency of cancer 
patients with diabetes on the palliative care wards. 
Patients with type II diabetes are reported to have 
a worse response to cancer chemotherapy, have more 
complications, and have a poorer prognosis than 
patients with cancer but without diabetes [5].
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The aim of the treatment
While with diabetes the aim of the treatment 
is normally to maintain blood glucose at nearly 
normal levels, the aim for diabetic patients in 
palliative care is different. Due to their marked 
insulin resistance, frequent infections and other 
symptoms, such as anorexia, nausea and vomit-
ing, maintaining the blood glucose at “normal” 
levels is very difficult, if not impossible. Intensive 
treatment with anti-diabetics may increase the 
risk of hypoglycaemia. As in palliative care one 
tries to control symptoms without inducing ad-
verse effects, wider ranges of blood glucose may 
be observed. The ranges between 8 and 15 mmol/L 
(150–250 mg/dL) are seen as safe and relatively 
symptom free [2]. Doctors and nurses need to 
realize that patients with long-standing diabe-
tes and marked insulin resistance may experience 
hypoglycaemia much earlier and with blood glu-
cose values which are in healthy people still seen 
as normal. The symptomatology of hypoglycaemia 
has much more influence on patients’ quality of 
life than hyperglycaemia. Mild hyperglycaemia 
by its diuretic effect may help to control some 
other symptoms in the terminally ill, such as heart 
failure and increased intracranial pressure. Main-
taining blood glucose within narrow limits with 
a marked risk of hypoglycaemia is justified only in 
cases of a long prognosis, where normoglycaemia 
can prevent some of the later consequences of 
diabetes (Table 1).
Dietary measures
It is often seen as cruel to limit patients with 
advanced cancer and diabetes with regard to their 
intake of sugar. However, if the occasional high in-
take causes hyperglycaemia and symptoms of thirst 
and lethargy, patients should be advised to change 
their habits. In most cases, if the intake of calo-
ries/sugar is regular, it is possible to allow the patient 
a higher sugar intake and increase the hypoglycaemic 
agents/insulin dose.
The choice of an oral hypoglycaemic 
agent
Metformin, a biguanide which increases the up-
take of glucose by the muscles, can be used either 
as monotherapy or as an adjunct to sulphonylu-
reas [6]. Metformin may contribute to an anti-cancer 
treatment effect by making less glucose available to 
the tumour [7, 8]. Traditionally, metformin has been 
seen as a not-such-a-good-choice in the case of 
heart failure, COPD or renal impairment, as it may 
increase the risk of lactic acidosis. This tradition 
is now being questioned because of the apparently 
Table 1. Suggested scheme for managing patients with diabetes and advanced cancer (modified from [2])
Clinical condition Intervention
Type II diabetes
Patients on oral hypoglycaemic agents
  Weight loss, decreased appetite Reduce oral hypoglycaemic drugs by 50%, monitor blood glucose 3 × week 
and when  symptoms are apparent. In some patients, oral agents can be fully 
discontinued. Use preferentially short-acting drugs. Correct for poor renal 
function
  Terminal phase Discontinue all oral hypoglycaemic agents, do not monitor blood glucose 
unless symptoms are apparent
  Patients with blood glucose 
  values higher than 15 mmol/L
Consider starting with long-acting insulin, check blood glucose once daily at 
6 pm. Use short-acting insulin to control symptoms, not blood glucose values
Type I diabetes
Stable nutritional status Maintain previous insulin regime, check blood glucose twice daily every 3 days
Reduced appetite Reduce insulin, check fasting blood glucose daily
Severe anorexia, nausea 
and vomiting
Change to short-acting insulin on top of long-acting insulin
Terminal phase Do not check blood glucoses unless symptoms are apparent. Reduce insulin. 
Administer only once daily low doses of long-acting insulin. Do not top up with 
short-acting insulin
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beneficial effect on cancer as stated above [9]. Gli-
clazide and tolbutamide are short-acting drugs and 
can be prescribed when the fasting blood glucose 
is between 8–12 mmol/L. The dose should be re-
duced or discontinued in patients who are not eating 
or are vomiting. Other hypoglycaemic agents are 
long-acting and their kinetics may be changed in 
the case of progressing renal and/or hepatic fail-
ure resulting in long-lasting and potentially fatal 
hypoglycaemias. In many patients who have been 
using oral hypoglycaemics for a number of years, 
the dose in the terminal phase can be reduced or 
the drugs may be discontinued without danger of 
symptomatic hyperglycaemia.
The choice of insulin
Short-acting insulin SC injections have been used 
traditionally to control the brittle pattern of dia-
betes in the terminally ill. A sliding scale of insulin 
is usually attached to the prescription providing 
guidelines for the nurses and family members on 
how to handle it in case of hyperglycaemia. However, 
this approach needs many blood glucose determina-
tions, which should be avoided as much as possible. 
An example of a sliding scale [2] is presented on 
Table 2.
However, these values may vary because of the in-
sulin resistance which may differ from one patient to 
another. Be careful in patients with newly-diagnosed 
diabetes, as the insulin resistance may be low and 
they may be very sensitive, even to low doses of 
insulin.
In a patient not on antibiotics or changing 
doses of steroids, one can check the blood glu-
cose once daily, usually at 6 pm, and administer 
long-acting insulin once daily, with or without oral 
hypoglycaemics. This regime may be maintained 
until the end, minimizing the number of blood 
glucose determinations.
The need for insulin can change rapidly when 
a patient recovers from an infection and starts to 
mobilize from bed with the aid of a physiotherapist. 
At the same time, the appetite usually increases. 
This dynamic should be followed by more intensive 
blood glucose monitoring.
Steroid diabetes
Many patients previously unknown to be diabet-
ics may develop diabetes after the administration of 
steroids. Glucocorticoids are prescribed to 30% of 
the palliative care population [10]. Dexamethazone 
prescribed to lower the intracranial pressure in the 
case of brain metastases is particularly notorious for 
this effect [11]. Hyperglycaemia may become appar-
ent many days or weeks after commencing therapy 
and may become insidious. Hyperglycaemia is usually 
steroid dose-related. The doses of steroids should be 
reviewed as frequently as the doses of hypoglycaemic 
agents and insulin. Leaving the patient on a high 
dose of dexamethazone is frequently unnecessary 
and may precipitate diabetes earlier but may also 
induce many other complications. Patients with ster-
oid diabetes who experience infections and are being 
treated with antibiotics may rapidly need less insulin 
and during such an instable period blood glucose 
should be determined 2–3 times a day.
Effects of other drugs on diabetes
Diuretics, which are often used to control ascites, 
may alter glucose control in diabetics. Thiazide diu-
retics and furosemide may produce hyperglycaemia 
[12]. Potassium-sparing diuretics such as Spironolac-
tone may cause hyperkalemia. Diabetic patients are 
particularly predisposed to this effect and this drug 
may cause type IV tubular acidosis or hyporeninemic 
hypoaldosteronism. 
The terminal phase
When the patient enters the terminal phase in 
the sense that dying is very close, he/she is usually 
not taking in any calories and drinking only a lit-
tle. In many of these patients, the determination 
of blood glucose can be kept to a minimum and 
the dose of insulin can be markedly reduced. In the 
case of non-insulin dependent diabetes, drugs and 
insulin can be discontinued. In insulin dependent 
diabetes, insulin should be administered until the 
end, in reduced doses [13]. Some clinicians stop de-
terminations of blood glucose and glucose is tested 
in a sample of urine, usually at 1 pm, providing the 
patient has an indwelling catheter. As steroids are 
frequently also discontinued at the same time, the 
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need for hypoglycaemic activity may be decreased. 
Hypoglycaemia can be difficult to recognize and may 
add to the symptoms of approaching death. 
Conclusion
Dying with diabetes is not an easy clinical con-
dition to manage. On the one hand, dying pa-
tients should experience the minimum burden of 
blood glucose monitoring and additional insulin 
injections; on the other, they should be free of the 
symptoms of diabetes. In general, hypoglycaemia 
is experienced as being much worse than hyperg-
lycaemia. Too strict blood glucose control and the 
brittle course of diabetes may increase the risk of 
hypoglycaemia. Usually, hyperglycaemia should be 
treated when there are symptoms of dry mouth and 
dehydration. Some dehydration may be helpful in 
the terminal stages of increased intracranial pressure 
and heart failure. In general in palliative care, the 
symptoms should be treated rather than the blood 
glucose values.
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